RARITAN, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) — Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) (the “Company”), one of the world’s largest pure-play in vitro diagnostics companies, today announced that one of its shareholders (the “Selling Shareholder”), an affiliate of The Carlyle Group, intends to offer for sale in an underwritten secondary offering 22,000,000 ordinary shares of the Company pursuant to a registration statement filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Additionally, the Selling Shareholder expects to grant the underwriters a 30-day option to purchase up to an additional 3,300,000 ordinary shares on the same terms and conditions.

By A Silva